{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:38:15Z","timestamp":1787931495090,"version":"build-2784847793"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clml.2023.08.012","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T21:05:24Z","timestamp":1692738324000},"page":"882-888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6650-5704","authenticated-orcid":false,"given":"Myo","family":"Htut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":false,"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":false,"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounzer","family":"Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn C.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1414-2387","authenticated-orcid":false,"given":"William","family":"Deraedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Zudaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-min","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Pacaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Akram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.08.012_bib0001","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.08.012_bib0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JOP.19.00335","article-title":"Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies","volume":"16","author":"Parrondo","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clml.2023.08.012_bib0003","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00277-021-04514-y","article-title":"Long-term outcome after allogeneic stem cell transplantation in multiple myeloma","volume":"100","author":"Luoma","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2023.08.012_bib0004","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbmt.2014.04.027","article-title":"The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation","volume":"20","author":"Donato","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2023.08.012_bib0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/cancers14010055","article-title":"Allogeneic stem cell transplantation in multiple myeloma","volume":"14","author":"Greil","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2023.08.012_bib0006","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/cncr.32060","article-title":"Is there still a role for stem cell transplantation in multiple myeloma?","volume":"125","author":"Mina","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.08.012_bib0007","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbmt.2020.02.020","article-title":"Relapse after allogeneic hematopoietic cell transplantation for multiple myeloma: survival outcomes and factors influencing them","volume":"26","author":"Chhabra","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2023.08.012_bib0008","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.advms.2020.08.003","article-title":"Allogeneic hematopoietic cell transplantation for multiple myeloma: a retrospective analysis of the Polish Myeloma Group","volume":"65","author":"Go\u0142os","year":"2020","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.clml.2023.08.012_bib0009","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.bbmt.2020.03.028","article-title":"Long-term follow-up of CALGB (Alliance) 100001: autologous followed by nonmyeloablative allogeneic transplant for multiple myeloma","volume":"26","author":"Holstein","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2023.08.012_bib0010","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.bbmt.2016.08.024","article-title":"Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease, and high-risk cytogenetic features","volume":"22","author":"Rasche","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2023.08.012_bib0011","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/bmt.2017.183","article-title":"Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients","volume":"52","author":"Montefusco","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2023.08.012_bib0012","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.3390\/ijms21124303","article-title":"CAR-T cell therapy","volume":"21","author":"Ahmad","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2023.08.012_bib0013","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.08.012_bib0014","series-title":"(Ciltacabtagene Autoleucel) [package insert]","year":"2022"},{"key":"10.1016\/j.clml.2023.08.012_bib0015","unstructured":"Janssen Biotech, Inc and Legend Biotech: CARVYKTI\u24c7 (ciltacabtagene autoleucel) Summary of Product Characteristics. Accessed: February 15, 2023. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/carvykti-epar-product-information_en.pdf."},{"key":"10.1016\/j.clml.2023.08.012_bib0016","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clml.2023.08.012_bib0017","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.clml.2023.08.012_bib0018","doi-asserted-by":"crossref","first-page":"abstr 8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.08.012_bib0019","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.08.012_bib0020","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.08.012_bib0021","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.08.012_bib0022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.08.012_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006684","article-title":"BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma","volume":"11","author":"Raghunandan","year":"2023","journal-title":"J Immunother Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:31Z","timestamp":1761871411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2152265023002720"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}